Clinical Trials
53 trialsINCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Grupo Español de Investigación en Neurooncología
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Radiation Therapy Oncology Group
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
Antineoplaston Therapy in Treating Children With Brain Tumors
Burzynski Research Institute
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
SCUSF1202
University of South Florida
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Jonsson Comprehensive Cancer Center
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
University of California, San Francisco
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Mayo Clinic
Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Alliance for Clinical Trials in Oncology
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Radiation Therapy in Treating Young Patients With Gliomas
Children's Oncology Group
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Temozolomide in Treating Patients With Low-Grade Glioma
University of California, San Francisco
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
National Cancer Institute (NCI)
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
Children's Oncology Group
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
National Cancer Institute (NCI)
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
University of Washington
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Stanford University
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
St. Jude Children's Research Hospital
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
National Cancer Institute (NCI)
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
BIBF 1120 for Recurrent High-Grade Gliomas
Dana-Farber Cancer Institute
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
National Cancer Institute (NCI)
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Marmara University